- Home
- USA vs HRMY Comparison
USA vs HRMY Comparison
Compare USA & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USA
- HRMY
- Stock Information
- Founded
- USA 1986
- HRMY 2017
- Country
- USA United States
- HRMY United States
- Employees
- USA N/A
- HRMY N/A
- Industry
- USA Finance Companies
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- USA Finance
- HRMY Health Care
- Exchange
- USA Nasdaq
- HRMY Nasdaq
- Market Cap
- USA N/A
- HRMY 1.8B
- IPO Year
- USA N/A
- HRMY 2020
- Fundamental
- Price
- USA $6.92
- HRMY $33.53
- Analyst Decision
- USA
- HRMY Strong Buy
- Analyst Count
- USA 0
- HRMY 9
- Target Price
- USA N/A
- HRMY $54.22
- AVG Volume (30 Days)
- USA 880.5K
- HRMY 626.9K
- Earning Date
- USA 01-01-0001
- HRMY 08-05-2025
- Dividend Yield
- USA 9.66%
- HRMY N/A
- EPS Growth
- USA N/A
- HRMY 13.13
- EPS
- USA N/A
- HRMY 2.62
- Revenue
- USA N/A
- HRMY $744,852,000.00
- Revenue This Year
- USA N/A
- HRMY $20.10
- Revenue Next Year
- USA N/A
- HRMY $18.01
- P/E Ratio
- USA N/A
- HRMY $12.49
- Revenue Growth
- USA N/A
- HRMY 20.62
- 52 Week Low
- USA $5.62
- HRMY $26.47
- 52 Week High
- USA $7.09
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- USA 63.95
- HRMY 57.00
- Support Level
- USA $6.84
- HRMY $31.70
- Resistance Level
- USA $6.96
- HRMY $33.69
- Average True Range (ATR)
- USA 0.07
- HRMY 0.88
- MACD
- USA 0.02
- HRMY 0.11
- Stochastic Oscillator
- USA 90.00
- HRMY 93.44
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.